Last week, senior editor Annalee Armstrong and staff writer Gabrielle Mason covered the Clinical Trials on Alzheimer’s Disease conference. We'll hear from them as they discuss the latest news and what surprised them.  

Also in this episode, we cover the week's biggest headlines including an investigation into Neuralink, Google’s DeepMind and why things aren't working out for PI3Ks.

To learn more about topics in this episode:

• Eisai, Biogen rocked by 2nd lecanemab death report ahead of Alzheimer's data reveal
• Facing a familiar side effect problem, Eisai makes the case for its next Alzheimer's drug after patient deaths
• Roche thins Alzheimer's program after phase 3 failure, may seek 'external partnerships'
• A winner is crowned in head-to-head Alzheimer's battle between Biogen's Aduhelm and Lilly
• Neuralink under federal investigation for animal testing practices: Reuters
• Elon Musk claims Neuralink is 6 months from implanting brain-computer interfaces in humans—and, someday, he'll be one of them
• 'Troubling' study finds Google's kidney disease-predicting AI performs worse in women—and may not have a quick fix
• In fresh blow to floundering PI3K space, FDA feedback drives MEI, Kyowa to halt blood cancer program
• Rigel scores green light in AML just 4 months after buying asset from Forma
• UPDATED: J&J bows out of Horizon bid as Amgen and Sanofi eye cash plays for rare disease drugmaker
• Pfizer plots €1.2B investment—and up to 500 new jobs—at Irish manufacturing plant
• Fierce JPM Week

"The Top Line" is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

See omnystudio.com/listener for privacy information.